
Freeline Therapeutics Holdings is a biotechnology business based in the US. Freeline Therapeutics Holdings shares (FRLN) are listed on the NASDAQ and all prices are listed in US Dollars. Freeline Therapeutics Holdings employs 235 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Freeline Therapeutics Holdings stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – FRLN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Freeline Therapeutics Holdings stock price (NASDAQ: FRLN)
Use our graph to track the performance of FRLN stocks over time.Freeline Therapeutics Holdings shares at a glance
Latest market close | $0.62 |
---|---|
52-week range | $0.46 - $1.29 |
50-day moving average | $0.56 |
200-day moving average | $0.75 |
Wall St. target price | $5.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.53 |
Buy Freeline Therapeutics Holdings stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Freeline Therapeutics Holdings stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Freeline Therapeutics Holdings price performance over time
Historical closes compared with the close of $0.62 from 2023-02-06
1 week (2023-01-31) | 5.62% |
---|---|
1 month (2023-01-06) | 25.51% |
3 months (2022-11-07) | -15.07% |
6 months (2022-08-05) | -28.90% |
1 year (2022-02-07) | -48.33% |
---|---|
2 years (2021-02-05) | -96.42% |
3 years (2020-02-03) | N/A |
5 years (2018-02-03) | N/A |
Freeline Therapeutics Holdings financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -50.15% |
Return on equity TTM | -90.95% |
Profit margin | 0% |
Book value | $1.06 |
Market capitalisation | $35.9 million |
TTM: trailing 12 months
Freeline Therapeutics Holdings share dividends
We're not expecting Freeline Therapeutics Holdings to pay a dividend over the next 12 months.
Freeline Therapeutics Holdings share price volatility
Over the last 12 months, Freeline Therapeutics Holdings's shares have ranged in value from as little as $0.46 up to $1.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Freeline Therapeutics Holdings's is 0.2933. This would suggest that Freeline Therapeutics Holdings's shares are less volatile than average (for this exchange).
Freeline Therapeutics Holdings overview
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. .
Freeline Therapeutics Holdings in the news
Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
Frequently asked questions
What percentage of Freeline Therapeutics Holdings is owned by institutions?Currently 58.412% of Freeline Therapeutics Holdings shares are held by institutions. How many people work for Freeline Therapeutics Holdings?
Latest data suggests 235 work at Freeline Therapeutics Holdings. When does the fiscal year end for Freeline Therapeutics Holdings?
Freeline Therapeutics Holdings's fiscal year ends in December. Where is Freeline Therapeutics Holdings based?
Freeline Therapeutics Holdings's address is: Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX What is Freeline Therapeutics Holdings's ISIN number?
Freeline Therapeutics Holdings's international securities identification number is: US35655L1070
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert